Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE

Jeffrey Kline, Donald M. Yealy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The EINSTEIN-PE trial showed that rivaroxaban has equal efficacy and a lower rate of bleeding than coumarins in the treatment of acute pulmonary embolism. We anticipate regulatory and consumer acceptance for rivaroxaban, representing the first new anticoagulant treatment for venous thromboembolism since the introduction of warfarin compounds 50 years ago.

Original languageEnglish (US)
Pages (from-to)378-380
Number of pages3
JournalNature Reviews Cardiology
Volume9
Issue number7
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Venous Thromboembolism
Anticoagulants
Coumarins
Warfarin
Pulmonary Embolism
Hemorrhage
Therapeutics
Rivaroxaban

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Venous thromboembolism : EINSTEIN transforms anticoagulant therapy in acute PE. / Kline, Jeffrey; Yealy, Donald M.

In: Nature Reviews Cardiology, Vol. 9, No. 7, 07.2012, p. 378-380.

Research output: Contribution to journalArticle

@article{b193c2e9089b4d658fadbbc4573c8027,
title = "Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE",
abstract = "The EINSTEIN-PE trial showed that rivaroxaban has equal efficacy and a lower rate of bleeding than coumarins in the treatment of acute pulmonary embolism. We anticipate regulatory and consumer acceptance for rivaroxaban, representing the first new anticoagulant treatment for venous thromboembolism since the introduction of warfarin compounds 50 years ago.",
author = "Jeffrey Kline and Yealy, {Donald M.}",
year = "2012",
month = "7",
doi = "10.1038/nrcardio.2012.65",
language = "English (US)",
volume = "9",
pages = "378--380",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Venous thromboembolism

T2 - EINSTEIN transforms anticoagulant therapy in acute PE

AU - Kline, Jeffrey

AU - Yealy, Donald M.

PY - 2012/7

Y1 - 2012/7

N2 - The EINSTEIN-PE trial showed that rivaroxaban has equal efficacy and a lower rate of bleeding than coumarins in the treatment of acute pulmonary embolism. We anticipate regulatory and consumer acceptance for rivaroxaban, representing the first new anticoagulant treatment for venous thromboembolism since the introduction of warfarin compounds 50 years ago.

AB - The EINSTEIN-PE trial showed that rivaroxaban has equal efficacy and a lower rate of bleeding than coumarins in the treatment of acute pulmonary embolism. We anticipate regulatory and consumer acceptance for rivaroxaban, representing the first new anticoagulant treatment for venous thromboembolism since the introduction of warfarin compounds 50 years ago.

UR - http://www.scopus.com/inward/record.url?scp=84862861602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862861602&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2012.65

DO - 10.1038/nrcardio.2012.65

M3 - Article

C2 - 22566060

AN - SCOPUS:84862861602

VL - 9

SP - 378

EP - 380

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 7

ER -